WHO also reported that global COVID-19 deaths keep declining. The VDH is no longer reporting COVID fatalities and cases in ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in US infants.

Covid-19 and RSV head data scientist dramatically quits saying she doesn’t trust RFK Jr department to use it ‘objectively’ - ...

Fiona Havers, who oversaw CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

A Seattle infectious disease doctor, whose work was pivotal early in the COVID pandemic, shares more on her experience with ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

Early evidence shows that nirsevimab substantially reduced emergency bronchiolitis cases and hospital admissions in infants ...

Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Cleveland health officials are warning residents after a 250% spike in COVID-19 viral levels was found in city wastewater.

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...